RESULTS OF USING THE MAGGIC HEART FAILURE RISK SCORE AND GALECTIN-3 LEVELS IN ASSESSING MORTALITY RISK IN PATIENTS WITH CHRONIC HEART FAILURE AND RHEUMATOID ARTHRITIS

Background. Chronic autoimmune inflammation in rheumatoid arthritis has a negative impact on the progression of atherosclerosis, morphofunctional parameters of the myocardium, blood pressure, and the risk of mortality in such patients. 
The aim of the study. To perform a comparative analysis of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) score coefficients and galectin-3 levels in patients with chronic heart failure with and without rheumatoid arthritis. 
Materials and methods. We examined 216 patients with heart failure. Two comparable groups were identified: the study group consisted of 100 patients with chronic heart failure and rheumatoid arthritis, the comparison group – of 116 patients with chronic heart failure without rheumatoid arthritis. The analysis of key laboratory and instrumental data and galectin-3 levels was performed. A regression analysis of the associations between the concentration of galectin-3 and the parameters determined using the MAGGIC heart failure risk score was carried out.
Results. The study showed significant statistical differences in the level of galectin-3: in the group of patients with rheumatoid arthritis – 17.4 ± 4.2 ng/ml, in patients without rheumatoid arthritis – 14.3 ± 3.1 ng/ml (p = 0.005). 
The average MAGGIG heart failure risk score in the group of patients with chronic heart failure and rheumatoid arthri-tis was 14 ± 2.1, without rheumatoid arthritis – 12 ± 1.4 (p = 0.01). The risk of mortality during the first year was 7.0 and 4.8 % (p = 0.02), within 3 years – 17.5 and 12.2 % (p = 0.04), respectively. Using regression analysis of interrela-tions of galectin-3 levels with mortality risk identified using the MAGGIC score, a statistically significant association was found (β = –0.04; SD = 10 ± 2.5; r = 0.46; r2 = 0.37; p = 0.002).
Conclusion. Patients with chronic heart failure and rheumatoid arthritis have higher levels of galectin-3 in their blood compared to people without rheumatoid arthritis. In addition, they have an increased risk of death according to the MAGGIC score. A statistically significant association of galectin-3 with the parameters of the MAGGIC heart failure risk score has been revealed.

1. Литература/References

2. Драпкина О.М., Бойцов С. А., Омельяновский В. В. Социально-экономический ущерб, обусловленный хронической СН, в Российской Федерации. Российский кардиологический журнал. 2021; 26(6): 4490. [Drapkina O.M., Boytsov S.A, Omelyanovsky V.V. Socioe-conomic impact of heart failure in Russia. Russian Journal of Cardio-

3. logy. 2021; 26(6): 4490. (In Russ.)]. doi:10.

4. /1560-4071-2021-4490.

5. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11):

6. [Clinical practice guidelines for Chronic heart failure. Russian

7. Journal of Cardiology. 2020; 25 (11): 4083. (In Russ.)]. doi:10.15829/1560-4071-2020-4083.

8. Chen J, Norling LV, Cooper D. Cardiac Dysfunction in Rheumatoid Arthritis: The Role of Inflammation. Cells. 2021; 10(4): 881. doi: 10.3390/cells10040881.

9. Анкудинов А.С., Калягин А.Н. Анализ взаимосвязи иммунологических факторов и воспалительных маркеров с течением хронической сердечной недостаточности на фоне ревматоидного артрита

10. Кардиология. 2018; 58 (s10): 4-8. [Ankudinov A.S., Kalyagin A.N. Analysis of the relationship of immunological factors and inflammatory markers with the course of chronic heart failure against the background of rheumatoid arthritis. Cardiology. 2018; 58 (s10): 4-8. (In Russ.)]. doi: 10.18087/cardio.2495

11. Khalid Y, Dasu N, Shah A. Incidence of congestive heart failure in rheumatoid arthritis: a review of literature and meta-regression analysis. ESC Heart Fail. 2020; 7(6): 3745-3753. doi: 10.1002/ehf2.12947.

12. Ferreira MB, Fonseca T, Costa R. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. Eur J Intern Med. 2021; 85: 41-49. doi: 10.1016/j.ejim.2020.11.002.

13. Ahlers MJ, Lowery BD, Farber-Eger E et al. Heart Failure Risk Associated With Rheumatoid Arthritis-Related Chronic Inflammation. J Am Heart Assoc. 2020; 9(10): e014661. doi: 10.1161/JAHA.119.014661

14. SCORE2 working group and ESC cardiovascular risk collaboration. European Heart Journal, ehab309. doi: 10.1093/eurheartj/ehab309

15. Mavrogeni SI. Pathophysiology and imaging of heart failure in women with autoimmune rheumatic diseases. Heart Fail Rev. 2019. PMID: 30830518 Review.

16. Park E, Griffin J, Bathon JM. Myocardial dysfunction and heart failure in rheumatoid arthritis. Arthritis Rheumatol. 2022; 74(2):184-199. doi: 10.1002/art.41979.

17. Подзолков В.И., Драгомирецкая Н.А., Казадаева А.В. Галектин-3 как маркер кардиоренального синдрома у больных хронической сердечной недостаточностью. Рациональная фармакотерапия в кардиологии. 2022; 18 (2): 153-159. [Podzolkov VI, Dragomiretskaya NA, Kazadaeva AV et al. Galectin-3 is a marker of cardiorenal syndrome in chronic heart failure. Rational pharmacotherapy in cardiology. 2022; 18 (2): 153-159. (In Russ.)]. doi: 10.20996/1819-6446-2022-04-04

18. Zaborska B, Sikora-Frąc M, Smarż K. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand? Int J Mol Sci. 2023; 24(17): 13111. doi: 10.3390/ijms241713111.

19. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Haran B, Javed B, Čelutkienė J, Chioncel O, Cleland GF, Coats JS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam SP, Lyon AR, McMurray JJV, Mebazaa A, Richard Mindham, Claudio Muneretto, Massimo Francesco Piepoli, Susanna Price, Rosano GMC, Ruschitzka F, Skibelund AK. ESC Scientific Document Group. 2021 ESC Guide lines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022: 24(1):4-131. doi:10.1093/eurheartj/ehab368.

20. Насонов Е.Л. Ревматология. Клинические рекомендации. М.: ГЭОТАР-Медиа; 2017. 464с. [Nasonov EL. Rheumatology. Clinical recommendations. Moscow: GEOTAR-Media; 2017. 464 p. (In Russ.)].

21. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. – М.: МедиаСфера, 2002. 312 с. [Rebrova OY. Statistical analysis of medical data. Application of the STATISTICA application software package. M.: Mediasphere, 2002. 312 p. (In Russ.)].

22. Ларина В.Н., Ойноткинова О.Ш., Лунев В.И. Фенотипы хронической сердечной недостаточности с сохраненной фракцией выброса у пациентов старшего возраста. Клиническая геронтология. 2023; 29 (7-8): 3-10. [Larina VN, Oinotkinova OSh, Lunev VI. Phenotypes of chronic heart failure with preserved ejection fraction in older patients. Clinical gerontology. 2023; 29 (7-8): 3-10. (In Russ.)]. doi: 10.26347/1607-2499202307-08003-010.

23. Хазова Е.В., Булашова О.В. Роль системного воспаления при сердечной недостаточности. Казанский медицинский журнал. 2021; 102 (4): 510-517. [Khazova EV, Bulashova OV. Kazan The role of systemic inflammation in heart failure. Kazansky Medical Journal. 2021; 102(4):510-517. (In Russ.)]. doi: 10.17816/KMJ2021-510.

24. Buleu F, Sirbu E, Caraba A. Heart Involvement in Inflammatory Rheumatic Diseases: A Systematic Literature Review. Medicina (Kaunas). 2019; 55(6): 249. doi: 10.3390/medicina55060249.

25. Rich DJ, Burns J, Freed BH. Meta-Analysis Global Group in Chronic (MAGGIC) heart failure risk score: validation of a simple tool for the prediction of morbidity and mortality in heart failure with preserved ejection fraction. J Am Heart Assoc. 2018; 7(20):e009594. DOI: 10.1161/JAHA.118.009594

26. Wu C, Lv Z, Li X. Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis. Heart Surg Forum. 2021; 24(2): E327-E332. doi: 10.1532/hsf.3547.